Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and biogenic amines in Parkinson's disease

Current Genomics

Volumn 14, Issue 8, 2013, Pages 518-533

  Dorszewska, Jolanta ^a   Prendecki, Michal ^a   Oczkowska, Anna ^a   Rozycka, Agata ^a   Lianeri, Margarita ^a   Kozubski, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

COMT; MAO; Monoamine transporters polymorphism; PD

Indexed keywords

BIOGENIC AMINE; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; LEVODOPA;

ARTICLE; CATECHOL METHYLTRANSFERASE GENE; DEGENERATIVE DISEASE; DEPRESSION; DOPAMINE GENE; GENE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MISSENSE MUTATION; MONOAMINE OXIDASE GENE; NERVE CELL PLASTICITY; NONHUMAN; NOREPINEPHRINE GENE; PARKINSON DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SEROTONIN GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84894032962     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202914666131210210241     Document Type: Article

References (137)

1. Gibb, W.R.; Lees, A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1991, 54(5), 388-396.
2. Zarow, C.; Lyness, S.A.; Mortimer, J.A.; Chui, H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol., 2003, 60(3), 337-341.
3. Gainetdinov, R.R.; Caron, M.G. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 261-284.
4. Eisenhofer, G.; Kopin, I.J.; Goldstein, D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev., 2004, 56(3), 331-349.
5. Hastings, T.G.; Lewis, D.A.; Zigmond, M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U S A., 1996, 93(5), 1956-1961.
6. Amara, S.G.; Sonders, M.S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend., 1998, 51(1-2), 87-96.
7. Schroeter, S.; Apparsundaram, S.; Wiley, R.G.; Miner, L.H.; Sesack, S.R.; Blakely, R.D. Immunolocalization of the cocaineand antidepressant-sensitive l-norepinephrine transporter. J. Comp. Neurol., 2000, 420(2), 211-232.
8. Nakamura M.; Ueno S.; Sano, A.; Tanabe, H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol. Psychiatry., 2000, 5(1), 32-38.
9. Lee, M.S.; Lyoo, C.H.; Ulmanen, I.; Syvänen, A.C.; Rinne, J.O. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci. Lett., 2001, 298(2), 131-134.
10. Lin, C.N.; Liu, H.C.; Tsai, S.J.; Liu, T.Y.; Hong, C.J. Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G). Eur. Neurol., 2002, 48(4), 207-209.
11. Parsian, A.; Racette, B.; Zhang, Z.H.; Rundle, M.; Perlmutter, J.S. Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups. Genomics, 2004, 83(3), 454-460.
12. th International Conference on Alzheimer's and Parkinson's Diseases. Barcelona, Spain, March 9-13, 2011. Neurodegener. Dis., 2011, 8, Supp. 1, P1.
13. Olanow, C.W. Levodopa/dopamine replacement strategies in Parkinson's disease: future directions. Movement Dis., 2008, 23, Suppl. 3, S613-S622.
14. Reilly, D.K.; Rivera-Calimlim, L.; Van Dyke, D. Catechol-Omethyltransferase activity: a determinant of levodopa response. Clin. Pharmacol. Ther., 1980, 28(2), 278-286.
15. Rivera-Calimlim, L.; Reilly, D.K. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. Clin. Pharmacol. Ther., 1984, 35(6), 804-809.
16. Lee, M.S.; Kim, H.S.; Cho, E.K.; Lim, J.H.; Rinne, J.O. COMT genotype and effectiveness of entacapone in patients with fluctuat ing Parkinson's disease. Neurology, 2002, 58(4), 564-567.
17. Goldstein, D.S.; Eisenhofer, G.; Kopin, I.J. Clinical catecholamine neurochemistry: a legacy of Julius Axelrod. Cell Mol. Neurobiol., 2006, 26(4-6), 695-702.
18. Udenfriend, S.; Titus, E.; Weissbach, H.; Peterson, R.E. Biogenesis and metabolism of 5-hydroxyindole compounds. J. Biol Chem., 1956, 219(1), 335-344.
19. Elliott, T.R. The action of adrenalin. J. Physiol., 1905, 32(5-6), 401-467.
20. Rubin, R.P. A Brief History of Great Discoveries in Pharmacology: In Celebration of the Centennial Anniversary of the Founding of the American Society of Pharmacology and Experimental Therapeutics. Pharmacol Rev., 2007, 59(4), 289-359.
21. Yu, A.J.; Dayan, P. Uncertainty, neuromodulation, and attention. Neuron, 2005, 46(4), 681-692.
22. Kalbitzer, J.; Deserno, L.; Schlagenhauf, F.; Beck, A.; Mell, T.; Bahr, G.; Buchholz, H.G.; Plotkin, M.; Buchert, R.; Kumakura, Y.; Cumming, P.; Heinz, A.; Rapp, M.A. Decline in prefrontal catecholamine synthesis explains age-related changes in cognitive speed beyond regional grey matter atrophy. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(9), 1462-1466.
23. Usher, M.; Cohen, J.D.; Servan-Schreiber, D.; Rajkowski J.; Aston-Jones, G. The role of locus coeruleus in the regulation of cognitive performance. Science, 1999, 283(5401), 549-554.
24. O'Donnell, J.; Zeppenfeld, D.; McConnell, E.; Pena, S.; Nedergaard, M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem. Res., 2012, 37(11), 2496-2512.
25. Sudhof, T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci., 2004, 27, 509-547.
26. Muñoz P, Huenchuguala S, Paris I, Segura-Aguilar J. Dopamine oxidation and autophagy. Parkinsons Dis., 2012, in press.
27. Wimalasena, K. Vesicular monoamine transporters: structurefunction, pharmacology, and medicinal chemistry. Med Res Rev., 2011, 31(4), 483-519.
28. Sudhof, T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci., 2004, 27, 509-547.
29. Richter, D. Adrenaline and amine oxidase. Biochem. J., 1937, 31(11), 2022-2028.
30. Foppoli, C.; Coccia, R.; Cini, C.; Rosei, M.A. Catecholamines oxidation by xanthine oxidase. Biochim. Biophys. Acta, 1997, 1334(2-3), 200-206.
31. Grossman, M.H.; Emanuel, B.S.; Budarf, M.L. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics, 1992, 12(4), 822-825.
32. Syvänen, A.C.; Tilgmann, C.; Rinne, J.; Ulmanen, I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics, 1997, 7(1), 65-71.
33. Lotta, T.; Vidgren, J.; Tilgmann, C.; Ulmanen, I.; Melén, K.; Julkunen, I.; Taskinen, J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry, 1995, 34(13), 4202-4210.
34. Nackley, A.G.; Shabalina, S.A.; Tchivileva, I.E.; Satterfield, K.; Korchynskyi, O.; Makarov, S.S.; Maixner, W.; Diatchenko, L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science, 2006, 314(5807), 1930-1933.
35. Zubieta, J.K.; Heitzeg, M.M.; Smith, Y.R.; Bueller, J.A.; Xu, K.; Xu, Y.; Koeppe, R.A.; Stohler, C.S.; Goldman, D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science, 2003, 299(5610), 1240-1243.
36. Winterer, G.; Goldman, D. Genetics of human prefrontal function. Brain Res. Brain Res. Rev., 2003, 43(1), 134-163.
37. Oroszi, G.; Goldman, D. Alcoholism: genes and mechanisms. Pharmacogenomics, 2004, 5(8), 1037-1048.
38. Funke, B.; Malhotra, A.K.; Finn, C.T.; Plocik, A.M.; Lake, S.L.; Lencz, T.; DeRosse, P.; Kane, J.M.; Kucherlapati, R. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav. Brain Funct., 2005, 1, 19.
39. Xie, T.; Ho, S.L. Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol. Pharmacol., 1999, 56(1), 31-38.
40. Xie, T.; Ho, S.L.; Li, L.S.; Ma, O.C. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov. Disord., 1997, 12(3), 426-427.
41. Yoritaka, A.; Hattori, N.; Yoshino, H.; Mizuno, Y. Catechol-Omethyltransferase genotype and susceptibility to Parkinson's disease in Japan. Short communication. J. Neural. Transm. 1997, 104(11-12), 1313-1317.
42. Kunugi, H.; Nanko, S.; Ueki, A.; Otsuka, E.; Hattori, M.; Hoda, F.; Vallada, H.P.; Arranz, M.J. Collier, D.A. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci. Lett., 1997, 221(2-3), 202-204.
43. Białecka, M.; Droździk, M.; Honczarenko, K.; Gawronska-Szklarz, B.; Stankiewicz, J.; Dabrowska, E.; Kubisiak, M.; Klodowska-Duda, G.; Opala, G. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur. Neurol., 2005, 53(2), 68-73.
44. McLeod, H.L.; Syvänen, A.C.; Githang'a, J.; Indalo, A.; Ismail, D.; Dewar, K.; Ulmanen, I.; Sludden, J. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics, 1998, 8(3), 195-199.
45. Bialecka, M.; Kurzawski, M.; Klodowska-Duda, G.; Opala, G.; Tan, E.K.; Drozdzik, M. The association of functional catechol-Omethyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet. Genomics, 2008, 18(9), 15-21.
46. Kiyohara, C.; Miyake, Y.; Koyanagi, M.; Fujimoto, T.; Shirasawa, S.; Tanaka, K.; Fukushima, W.; Sasaki, S.; Tsuboi, Y.; Yamada, T.; Oeda, T.; Shimada, H.; Kawamura, N.; Sakae, N.; Fukuyama, H.; Hirota, Y.; Nagai, M.; Fukuoka Kinki Parkinson's Disease Study Group. Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population. BMC Neurol., 2011, 11, 89.
47. Zhu, B.T. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab., 2002, 3(3), 321-349.
48. Tunbridge, E.M.; Harrison, P.J.; Weinberger, D.R. Catechol-omethyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry., 2006, 60(2), 141-151.
49. Dickinson, D.; Elvevag, B. Genes, cognition and brain through a COMT lens. Neuroscience, 2009, 164(1), 72-87.
50. Farrell, S.M.; Tunbridge, E.M.; Braeutigam, S.; Harrison, P.J. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol. Psychiatry., 2012, 71(6), 538-544.
51. Chen, J.; Song, J.; Yuan, P.; Tian, Q.; Ji, Y.; Ren-Patterson, R.; Liu, G.; Sei, Y.; Weinberger, D.R. Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development. J. Biol. Chem., 2011, 286(40), 34752-34760.
52. Chong, D.J.; Suchowersky, O.; Szumlanski, C.; Weinshilboum, R.M.; Brant, R.; Campbell, N.R. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol., 2000, 23(3), 143-148.
53. Tan, E.K.; Cheah, S.Y.; Fook-Chong, S.; Yew, K.; Chandran, V.R.; Lum, S.Y.; Yi, Z. Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2005, 137B(1), 1-4.
54. Bialecka, M.; Kurzawski, M.; Roszmann, A.; Robowski, P.; Sitek, E.J.; Honczarenko, K.; Gorzkowska, A.; Budrewicz, S.; Mak, M.; Jarosz, M.; Goła{ogonek}b-Janowska, M.; Koziorowska-Gawron, E.; Drozdzik, M.; Sławek, J. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenet. Genomics, 2012, 22(10), 716-724.
55. Hotamisligil, G.S.; Girmen, A.S.; Fink, J.S.; Tivol, E.; Shalish, C.; Trofatter, J.; Baenziger, J.; Diamond, S.; Markham, C.; Sullivan, J. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov. Disord., 1994, 9(3), 305-310.
56. Nanko, S.; Ueki, A.; Hattori, M. No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms. Neurosci. Lett., 1996, 204(1-2), 125-127.
57. Planté-Bordeneuve, V.; Taussig, D.; Thomas, F.; Said, G.; Wood, N.W.; Marsden, C.D.; Harding, A.E. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology, 1997, 48(6), 1589-1593.
58. Costa-Mallen, P.; Checkoway, H.; Fishel, M.; Cohen, A.W.; Smith-Weller, T.; Franklin, G.M.; Swanson, P.D.; Costa, L.G. The EcoRV genetic polymorphism of human monoamine oxidase type A is not associated with Parkinson's disease and does not modify the effect of smoking on Parkinson's disease. Neurosci. Lett., 2000, 278(1-2), 33-36.
59. Kurth, J.H.; Kurth, M.C.; Poduslo, S.E.; Schwankhaus, J.D. Association of a monoamine oxidase B allele with Parkinson's disease. Ann. Neurol., 1993, 33(4), 368-372.
60. Morimoto, Y.; Murayama, N.; Kuwano, A.; Kondo, I.; Yamashita, Y.; Mizuno, Y. Association analysis of a polymorphism of the monoamine oxidase B gene with Parkinson's disease in a Japanese population. Am. J. Med. Genet., 1995, 60(6), 570-572.
61. Ho, S.L.; Kapadi, A.L.; Ramsden, D.B.; Williams, A.C. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann. Neurol., 1995, 37(3), 403-405.
62. Costa, P.; Checkoway, H.; Levy, D.; Smith-Weller, T.; Franklin, G.M.; Swanson, P.D.; Costa, L.G. Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease. Am. J. Med. Genet., 1997, 74(2), 154-156.
63. Mellick, G.D.; Buchanan, D.D.; McCann, S.J.; James, K.M.; Johnson, A.G.; Davis, D.R.; Liyou, N.; Chan, D.; Le Couteur, D.G. Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov. Disord., 1999, 14(2), 219-224.
64. Hernan, M.A.; Checkoway, H.; O'Brien, R.; Costa-Mallen, P.; De Vivo, I.; Colditz, G.A.; Hunter, D.J.; Kelsey, K.T.; Ascherio, A. MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology, 2002, 58(9), 1381-1387.
65. Singh, M.; Khan, A.J.; Shah, P.P.; Shukla, R.; Khanna, V.K.; Parmar, D. Polymorphism in environment responsive genes and association with Parkinson disease. Mol. Cell Biochem., 2008, 312(1-2), 131-138.
66. Morino, H.; Kawarai, T.; Izumi, Y.; Kazuta, T.; Oda, M.; Komure, O.; Udaka, F; Kameyama, M.; Nakamura, S.; Kawakami, H. A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. Ann. Neurol., 2000, 47(4), 528-531.
67. Kimura M, Matsushita S, Arai H, Takeda A, Higuchi S. No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease. Ann. Neurol., 2001, 49(2), 276-277.
68. Albani, D.; Vittori, A.; Batelli, S.; Polito, L.; De Mauro, S.; Galimberti, D.; Scarpini, E.; Lovati, C.; Mariani, C.; Forloni, G. Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy. Eur. Neurol., 2009, 62(2), 120-123.
69. Zhang, J.L.; Yang, J.F.; Chan, P. No association between polymorphism of serotonin transporter gene and depression in Parkinson's disease in Chinese. Neurosci. Lett., 2009, 455(3), 155-158.
70. Lee, J.Y.; Cho, J.; Lee, E.K.; Park, S.S.; Jeon, B.S. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. Mov. Disord., 2011, 26(1), 73-79.
71. Güzey, C.; Allard, P.; Brännström, T.; Spigset, O. Radioligand binding to brain dopamine and serotonin receptors and transporters in Parkinson's disease: relation to gene polymorphisms. Int. J. Neurosci., 2012, 122(3), 124-132.
72. Kosenko, E.; Kaminsky, Y.; Kaminsky, A.; Valencia, M.; Lee, L.; Hermenegildo, C.; Felipo, V. Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic. Res., 1997, 27(6), 637-644.
73. Gotz, M.E.; Fischer, P.; Gsell, W.; Riederer, P.; Streifler, M.; Simanyi, M.; Müller, F.; Danielczyk, W. Platelet monoamine oxidase B activity in dementia. A 4-year follow-up. Dement. Geriatr. Cogn. Disord., 1998, 9(2), 74-77.
74. Bortolato, M.; Shih, J.C. Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int. Rev. Neurobiol., 2011, 100, 13-42.
75. Garrick, N.A.; Murphy, D.L. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology (Berl)., 1980, 72(1), 27-33.
76. Bach, A.W.; Lan, N.C.; Johnson, D.L.; Abell, C.W.; Bembenek, M.E.; Kwan, S.W.; Seeburg, P.H.; Shih, J.C. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. U S A., 1988, 85(13), 4934-4938.
77. Grimsby, J.; Chen, K.; Wang, L.J.; Lan, N.C.; Shih, J.C. Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc. Natl. Acad. Sci. U S A, 1991, 88(9), 3637-3641.
78. Zhu, Q.S.; Grimsby, J.; Chen, K.; Shih, J.C. Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J. Neurosci., 1992, 12(11), 4437-4446.
79. Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry, 2009, 48(20), 4220-4230.
80. Konradi, C.; Kornhuber, J.; Froelich, L.; Fritze, J.; Heinsen, H.; Beckmann, H.; Schulz, E.; Riederer, P. Demonstration of monoamine oxidase-A and-B in the human brainstem by a histochemical technique. Neuroscience, 1989, 33(2), 383-400.
81. Sharp, T.; Umbers, V.; Gartside, S.E. Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br. J. Pharmacol., 1997, 121(5), 941-946.
82. Brunner, H.G.; Nelen, M.; Breakefield, X.O.; Ropers, H.H.; van Oost, B.A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science, 1993a, 262(5133), 578-580.
83. Brunner, H.G.; Nelen, M.R.; van Zandvoort, P.; Abeling, N.G.; van Gennip, A.H.; Wolters, E.C.; Kuiper, M.A.; Ropers, H.H.; van Oost, B.A. X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am. J. Hum. Genet., 1993b, 52(6), 1032-1039.
84. Black, G.C.; Chen, Z.Y.; Craig, I.W.; Powell, J.F. Dinucleotide repeat polymorphism at the MAOA locus. Nucleic Acids Res., 1991, 19(3), 689.
85. Hinds, H.L.; Hendriks, R.W.; Craig, I.W.; Chen, Z.Y. Characterization of a highly polymorphic region near the first exon of the human MAOA gene containing a GT dinucleotide and a novel VNTR motif. Genomics, 1992, 13(3), 896-897.
86. Lim, L.C.; Powell, J.F.; Murray, R.; Gill, M. Monoamine oxidase A gene and bipolar affective disorder. Am. J. Hum. Genet., 1994, 54(6), 1122-1124.
87. Sabol, S.Z.; Hu, S.; Hamer, D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet., 1998, 103(3), 273-279.
88. Furlong, R.A.; Ho, L.; Rubinsztein, J.S.; Walsh, C.; Paykel, E.S.; Rubinsztein, D.C. Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, metaanalyses, and sequencing of the promoter. Am. J. Med. Genet., 1999, 88(4), 398-406.
89. Yu, Y.W.; Tsai, S.J.; Hong, C.J.; Chen, T.J.; Chen, M.C.; Yang, C.W. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology, 2005, 30(9), 1719-1723.
90. Hotamisligil, G.S., Breakefield, X.O. Human monoamine oxidase A gene determines levels of enzyme activity. Am. J. Hum. Genet., 1991, 49(2), 383-392.
91. Li, J.; Kang, C.; Zhang, H.; Wang, Y.; Zhou, R.; Wang, B.; Guan, L.; Yang, L.; Faraone, S.V. Monoamine oxidase A gene polymorphism predicts adolescent outcome of attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2007, 144B(4), 430-433.
92. Williams-Gray, C.; Goris, A.; Foltynie, T.; Compston, A.; Sawcer, S.; Barker, R.A. No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease. J. Neurol., 2009, 256(1), 132-133.
93. Berretta, N.; Freestone, P.S.; Guatteo, E.; de Castro, D.; Geracitano, R.; Bernardi, G.; Mercuri, N.B.; Lipski, J. Acute effects of 6-hydroxydopamine on dopaminergic neurons of the rat substantia nigra pars compacta in vitro. Neurotoxicology, 2005, 26(5), 869-881.
94. Jayanthi, L.D.; Ramamoorthy, S. Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants. AAPS J., 2005, 7(3), E728-738.
95. Zhao, G.; Zang, S.Y.; Zheng, X.W.; Zhang, X.H.; Guo, L.H. Bakuchiol analogs inhibit monoamine transporters and regulate mono aminergic functions. Biochem. Pharmacol., 2008, 75(9), 1835-1847.
96. Vandenbergh, D.J.; Persico, A.M.; Hawkins, A.L., Griffin, C.A.; Li, X.; Jabs, E.W.; Uhl, G.R. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics, 1992, 14(4), 1104-1106.
97. Boeve, B.F.; Silber, M.H.; Parisi, J.E.; Dickson, D.W.; Ferman, T.J.; Benarroch, E.E.; Schmeichel, A.M.; Smith, G.E.; Petersen, R.C.; Ahlskog, J.E.; Matsumoto, J.Y.; Knopman, D.S.; Schenck, C.H.; Mahowald, M.W. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology, 2003, 61(1), 40-45.
98. Ryu, S.H., Lee, S.H.; Lee, H.J.; Cha, J.H.; Ham, B.J.; Han, C.S.; Choi, M.J.; Lee, M.S. Association between norepinephrine transporter gene polymorphism and major depression. Neuropsychobiology, 2004, 49(4), 174-177.
99. Gesi, M.; Soldani, P.; Giorgi, F.S.; Santinami, A.; Bonaccorsi, I.; Fornai, F. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev., 2000, 24(6), 655-668.
100. McMillan, P.J.; White, S.S.; Franklin, A.; Greenup, J.L.; Leverenz, J.B.; Raskind, M.A.; Szot, P. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res., 2011, 1373, 240-252.
101. Gaspar, P.; Duyckaerts, C.; Alvarez, C.; Javoy-Agid, F.; Berger, B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann. Neurol., 1991, 30(3), 365-374.
102. Jonsson, E.G.; Nöthen, M.M.; Gustavsson, J.P.; Neidt, H.; Bunzel, R.; Propping, P.; Sedvall, G.C. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res., 1998, 79(1), 1-9.
103. Park, S.; Kim, J.W.; Yang, Y.H.; Hong, S.B.; Park, M.H.; Kim, B.N.; Shin, M.S.; Yoo, H.J.; Cho, S.C. Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder. Behav. Brain Funct., 2012, 8, 22.
104. Gainetdinov, R.R.; Caron, M.G. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 261-284.
105. Kulisevsky, J.; Pagonabarraga, J.; Pascual-Sedano, B.; Gironell, A.; García-Sánchez, C.; Martínez-Corral, M. Motor changes during sertraline treatment in depressed patients with Parkinson's disease. Eur. J. Neurol., 2008, 15(9), 953-959.
106. Archer, T.; Fredriksson, A. Influence of noradrenaline denervation on MPTP-induced deficits in mice. J. Neural. Transm., 2006, 113(9), 1119-1129.
107. Jonsson, E.G.; Nothen, M.M.; Gustavsson, J.P.; Neidt, H.; Bunzel, R.; Propping, P.; Sedvall, G.C. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res., 1998, 79(1), 1-9.
108. Wendland, J.R.; Martin, B.J.; Kruse, M.R.; Lesch, K.P.; Murphy, D.L. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol. Psychiatry, 2006, 11(3), 224-226.
109. Bisso-Machado, R.; Ramallo, V.; Tarazona-Santos, E.; Salzano, F.M.; Bortolini, M.C.; Hünemeier, T. 5-HTTLPR genetic diversity and mode of subsistence in Native Americans. Am. J. Phys. Anthropol.,. 2013, in press.
110. Ming, Q.S.; Zhang, Y.; Chai, Q.L.; Chen, H.Y.; Hou, C.J.; Wang, M.C.; Wang, Y.P.; Cai, L.; Zhu, X.Z.; Yi, J.Y.; Yao, S.Q. Interaction between a serotonin transporter gene promoter region polymorphism and stress predicts depressive symptoms in Chinese adolescents: a multi-wave longitudinal study. BMC Psychiatry, 2013, 13(1), 142.
111. Horjales-Araujo, E.; Demontis, D.; Lund, E.K.; Vase, L.; Finnerup, N.B.; Borglum, A.D.; Jensen, T.S.; Svensson, P. Emotional modulation of muscle pain is associated with polymorphisms in the serotonin transporter gene. Pain, 2013, 154(8), 1469-76.
112. Tomoda, A.; Nishitani, S.; Matsuura, N.; Fujisawa, T.X.; Kawatani, J.; Toyohisa, D.; Ono, M.; Shinohara, K. No interaction between serotonin transporter gene (5-HTTLPR) polymorphism and adversity on depression among Japanese children and adolescents. BMC Psychiatry, 2013, 13, 134.
113. Hsu, L.J.; Sagara, Y.; Arroyo, A.; Rockenstein, E.; Sisk, A.; Mallory, M.; Wong, J.; Takenouchi, T.; Hashimoto, M.; Masliah, E. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol., 2000, 157, 401-410.
114. Bergman, H.; Feingold, A.; Nini, A.; Raz, A.; Slovin, H.; Abeles, M.; Vaadia, E. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci., 1998, 21, 32-38.
115. Cabin, D.E.; Shimazu, K.; Murphy, D.; Cole, N.B.; Gottschalk, W.; McIlwain, K.L.; Orrison, B.; Chen, A.; Ellis, C.E.; Paylor, R.; Lu, B.; Nussbaum, R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci., 2002, 22(20), 8797-8807.
116. Djamgoz, M.B.; Hankins, M.W.; Hirano, J.; Archer, S.N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res., 1997, 37(24), 3509-3529.
117. Singaram, C.; Ashraf, W.; Gaumnitz, E.A.; Torbey, C.; Sengupta, A.; Pfeiffer, R.; Quigley, E.M. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet, 1995, 346(8979), 861-864.
118. Bouallegue, A.; Yamaguchi, N. Nitric oxide inhibits the bradykinin B2 receptor-mediated adrenomedullary catecholamine release but has no effect on adrenal blood flow response in vivo. J. Pharmacol. Sci., 2005, 98(2), 151-160.
119. Garthwaite, J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci., 1991, 14(2), 60-67.
120. Tjen-A-Looi, S.C.; Phan, N.T.; Longhurst, J.C. Nitric oxide modulates sympathoexcitatory cardiac-cardiovascular reflexes elicited by bradykinin. Am. J. Physiol. Heart Circ. Physiol., 2001, 281(5), H2010-H2017.
121. Uchiyama, Y.; Morita, K.; Kitayama, S.; Suemitsu, T.; Minami, N.; Miyasako, T.; Dohi, T. Possible involvement of nitric oxide in acetylcholine-induced increase of intracellular Ca2+ concentration and catecholamine release in bovine adrenal chromaffin cells. Jpn. J. Pharmacol., 1994, 65(1), 73-77.
122. Ward, L.E.; Hunter, L.W.; Grabau, C.E.; Tyce, G.M.; Rorie, D.K. Nitric oxide reduces basal efflux of catecholamines from perfused dog adrenal glands. J. Auton. Nerv. Syst., 1996, 61(3), 235-242.
123. Goldstein, D.S.; Holmes, C.S.; Dendi, R.; Bruce, S.R.; Li, S.T. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology, 2002, 58(8), 1247-1255.
124. Goldstein, D.S.; Holmes, C.; Sharabi, Y.; Brentzel, S.; Eisenhofer, G. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology, 2003, 60(8), 1327-1332.
125. Goldstein, D.S.; Holmes, C.; Li, S.T.; Bruce, S.; Metman, L.V.; Cannon, R.O. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med., 2000, 133(5), 338-347.
126. Jeske, N.A.; Berg, K.A.; Cousins, J.C.; Ferro, E.S.; Clarke, W.P.; Glucksman, M.J.; Roberts, J.L. Modulation of bradykinin signaling by EP24.15 and EP24.16 in cultured trigeminal ganglia. J. Neurochem., 2006, 97(1), 13-21.
127. Félétou, M.; Galizzi, J.P.; Levens, N.R. NPY receptors as drug targets for the central regulation of body weight. CNS Neurol. Disord. Drug Targets, 2006, 5(3), 263-274.
128. Gibbs, J.L.; Diogenes, A.; Hargreaves, K.M. Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors. Br. J. Pharmacol., 2007, 150(1), 72-79.
129. Sun, R.Q.; Tu, Y.J.; Lawand, N.B.; Yan, J.Y.; Lin, Q.; Willis, W.D. Calcitonin gene-related peptide receptor activation produces PKAand PKC-dependent mechanical hyperalgesia and central sensitization. J. Neurophysiol., 2004, 92(5), 2859-2866.
130. Yamada, T.; McGeer, P.L.; Baimbridge, K.G.; McGeer, E.G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res., 1990, 526(2), 303-307.
131. Granovsky, Y.; Schlesinger, I.; Fadel, S.; Erikh, I.; Sprecher, E.; Yarnitsky, D. Asymmetric pain processing in Parkinson's disease. Eur. J. Neurol., 2013, 20(10), 1375-82.
132. Marshall, J.; Schnieden, H. Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. J. Neurol. Neurosurg. Psychiatry, 1966, 29(3), 214-218.
133. Arai, A.; Tomiyama, M.; Kannari, K.; Kimura, T.; Suzuki, C.; Watanabe, M.; Kawarabayashi, T.; Shen, H.; Shoji, M. Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse, 2008, 62(8), 632-635.
134. Sethi, K. Levodopa unresponsive symptoms in Parkinson disease. Mov. Disord., 2008, 23 Suppl 3: S521-533.
135. Davidson, D.F.; Grosset, K.; Grosset, D. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites. Ann. Clin. Biochem., 2007, 44(4), 364-368.
136. Hinz, M.; Stein, A.; Uncini, T. Amino acid management of Parkinson's disease: a case study. Int. J. Gen. Med., 2011, 4, 165-174.
137. Ng, K.Y.; Chase, T.N.; Colburn, R.W.; Kopin, I.J. L-Dopa-induced release of cerebral monoamines. Science, 1970, 170(3953), 76-77.